JIJaved Iqbal

Javed Iqbal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javed Iqbal has a total of 243 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Serial glucose-to-potassium ratio burden predicts long-term outcomes after aneurysmal subarachnoid hemorrhage

    by Gursant Atwal, Javed Iqbal, Zinat Annaev, Ather Iqbal, Matthew Tai-Lin Huang, Zachary Daniel Taub, Emily Hazel Patzke, Sophia Girgenti, Justine Chee, Sameera Khan, et al.

  • TIE2 links MEKK3–KLF2/4 and PI3K signaling in cerebral cavernous malformation

    by Lun Li, Marco Castro, Hiroki Hongo, Jian Ren, Robert Shenkar, Rashad Jabarkheel, Siqi Gao, Sweta Narayan, Maxwell Frankfurter, Alan T. Tang, et al.

    Cerebral cavernous malformations (CCMs) are vascular lesions in the central nervous system that can cause strokes and seizures. Aggressive CCM growth follows an endothelial cell two-hit mechanism in which enhanced MEKK3–KLF2/4 signaling stimulates PI3K signaling, but how these pathways are linked has been undefined. Here, we use human CCM specimens, two mouse models of CCM disease, and primary human endothelial cells to examine the roles of the major endothelial growth factor receptors, VEGFR2 and TIE2. We find no evidence of augmented VEGFR2 signaling in CCM lesions, and neither genetic nor pharmacologic blockade of VEGFR2 reduced CCM formation in mouse models. Instead, we observe markedly increased phospho-TIE2 levels in human and mouse CCM lesions, MEKK3–KLF2/4-driven induction of TIE2 receptor expression, and almost complete rescue of CCM formation following genetic or pharmacologic TIE2 blockade in mouse models. Our studies identify TIE2 as the molecular link between the MEKK3–KLF2/4 and PI3K signaling pathways during CCM formation and suggest that targeting TIE2 may be an effective means to treat human CCM disease.


  • Relevance of Lesion Volume as an Outcome in Cerebral Cavernous Malformation Drug Trial: Exploratory Analyses in Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept

    by Roberto J. Alcazar-Felix, Richard E. Thompson, Agnieszka Stadnik, Serena Kinkade, Georgio Sader, Aditya Jhaveri, Justine Lee, Javed Iqbal, Sean P. Polster, Robert Shenkar, et al.

    BACKGROUND AND OBJECTIVES: It is not clear whether changes in lesion volume might represent a clinically relevant and statistically advantageous outcome parameter in early phase trials aimed at preventing bleeding in cerebral cavernous malformations (CCM). METHODS: We examined prospective changes in CCM lesion volume in the double-blinded AT CASH EPOC trial (clinicaltrials.gov NCT02603328). We correlated these with symptomatic hemorrhage (SH) events, contemporaneously assessed changes in lesional iron content by quantitative susceptibility mapping (QSM) on MRI, and objective (modified Rankin Scale (mRS)) and subjective (Euro-QoL Visual Analog Scale [EQ-VAS]) functional status. We also simulated sample sizes needed to detect potential effects on lesion volume. RESULTS: There was excellent correlation between independently assessed maximum lesion diameter and CCM lesion volume (R 2 = 0.68, P < .0001). The mean (SD) percentage change in lesion volume per year was +6 (65) and +18 (94) in atorvastatin and placebo patients, respectively ( P = .43). All cases with SH had increases in lesion volume and increases in mean lesional iron content by QSM, and most had declines in functional status on mRS and EQ-VAS, but there were no overall meaningful correlations of changes in lesion volume with concomitant changes in mean lesional QSM, mRS, or EQ-VAS (all R/R 2 < 0.5 and Bonferroni corrected P > .05), including in brainstem lesions analyzed separately. Sample size simulations indicate larger case numbers needed to demonstrate an effect on change in lesion volume than those needed to detect an effect on QSM change with α = 0.05 and β = 0.8, and even larger samples to detect effects on the number of cases with increased or decreased lesion volume. CONCLUSION: Changes in lesion volume occur frequently in CCM lesions after recent SH, but do not correlate with biomarkers of lesional bleeding, nor reflect functional changes, and are not statistically advantageous compared with QSM measures in detecting potential drug effects.

  • Open Access

    Global perspective of neurosurgery practice in lower middle-income countries: challenges, opportunities, and the path forward

    by Javed Iqbal, Ansa Naseem, Muhammad Arsalan Bashir, Kivanc Yangi, Ismail Bozkurt, Bipin Chaurasia


  • Open Access

    Surgery of craniosynostosis: a historical review

    by Javed Iqbal, Kivanc Yangi, Ansa Mbbs Naseem, Carlos E. Bs Calderon Valero, Bipin Chaurasia

    Calvarial sutures and skull-shape deformities have been recognized since ancient times, but their direct link to premature suture fusion was first established in the 19th century. The earliest surgical attempts for craniosynostosis emerged in 1890 with strip craniectomy, though early outcomes were largely unsuccessful. Surgical progress stagnated for decades due to complications and skepticism surrounding these techniques. The 20th century brought significant advancements, beginning with successful strip craniectomies in the 1920s and later attempts to prevent re-ossification through material barriers. The late 1960s marked a pivotal shift with the introduction of cranial vault remodeling, followed by the integration of external cranial vault devices and helmet therapy in the 1980s. By the 1990s, endoscopic strip craniectomy revolutionized treatment by minimizing invasiveness and blood loss. Despite these innovations, debates persist regarding optimal surgical timing, long-term outcomes, and patient adherence to treatment. Emerging technologies such as 3D imaging, artificial intelligence, and personalized medicine hold promise for the future of craniosynostosis management.


  • Open Access

    Demographic and regional patterns of epilepsy-related mortality in the USA: Insights from CDC WONDER data

    by Javed Iqbal, Muhammad Ashir Shafique, Burhanuddin Sohail Rangwala, Hafsah Alim Ur Rahman, Muhammad Abdullah Naveed, Afia Fatima, Ahila Ali, Tirath Patel, Moosa Abdur Raqib, Muhammad Saqlain Mustafa, et al.

    Background: Epilepsy poses significant challenges globally, with varied clinical, social, and economic impacts. Despite advances in treatment, epilepsy-related mortality remains a concern. This study aimed to analyze the demographic and regional distributions of epilepsy-related mortality in the United States (U.S.) from 1999 to 2020, identifying high-risk populations for targeted interventions. Methods: Data on death certificates were obtained from the 1999 to 2020 Centers for Disease Control and Prevention Wide-Ranging Online Study Epidemiologic Research (CDC-WONDER) database. We gathered data on demographics, place of death, and urban/rural classification. Mortality rates per 100,000 people were computed and classified according to state, year, sex, race/ethnicity, and urban/rural status. Trends were examined using Joinpoint regression. Results: A total of 12,573 deaths (age <35), 22,947 (35–64), and 21,782 (65+) were attributed to epilepsy. Mortality rates varied by age group, sex, race/ethnicity, and region. Trends showed significant increases, notably in middle-aged and older adults, with higher rates in males and nonHispani, African American populations. Conclusion: Epilepsy-related mortality exhibits demographic and regional disparities in the U.S. Understanding these patterns can guide targeted interventions to mitigate mortality risk.


  • An examination of seizure-free outcome and visual field deficits: Anterior temporal lobectomy versus selective amygdalohippocampectomy for temporal lobe epilepsy—a systematic review and meta-analysis for comprehensive understanding

    by Burhanuddin Sohail Rangwala, Hussain Sohail Rangwala, Muhammad Ashir Shafique, Muhammad Saqlain Mustafa, Fnu Danish, Sahil Kumar, Tooba Noor, Areej Shakil, Amna Qamber, Syeda Mahrukh Fatima Zaidi, et al.

    Background This study compares Selective Amygdalohippocampectomy (SAHE) and Anterior Temporal Lobectomy (ATL) for temporal lobe epilepsy (TLE), focusing on seizure control and visual field deficits (VFD). While previous research suggests potential benefits of SAHE, this meta-analysis aims to clarify the comparative effectiveness of bothprocedures. Methods This study adhered to PRISMA guidelines, comparing seizure outcomes and VFDs between SAHE and ATL for temporal lobe epilepsy. Comprehensive data extraction and meta-analysis revealed comparable efficacy, with SAHE potentially offering advantages in VFD risk reduction. Quality assessment ensured methodological rigor. Results 29 studies comparing SAHE and ATL for TLE. Seizure freedom analysis encompassed 23 studies (n = 3238), showing no significant difference between SAHE and ATL (RR = 0.96, 95% CI = 0.89–1.03, P = 0.26). SAHE exhibited significantly lower visual field deficits (RR = 0.87, 95% CI = 0.78–0.97, P = 0.01). Subgroup analyses highlighted differences between transsylvian SAHE and ATL but not transcortical SAHE. No significant difference was found in seizure freedom between SAHE and ATL in patients with hippocampal sclerosis. Conclusions ATL is more effective than transsylvian SAHE in achieving seizure freedom. However, no significant difference in seizure freedom was observed between transcortical SAHE and ATL. There were no notable differences in seizure outcomes between the two techniques in patients with hippocampal sclerosis. In contrast, SAHE carries a lower risk of postoperative visual field deficits compared to ATL.


  • Evaluating efficacy and safety of laser interstitial thermal therapy in patients with newly diagnosed and recurrent glioblastoma: a systematic review and meta-analysis

    by Hussain Sohail Rangwala, Muhammad Ashir Shafique, Muhammad Saqlain Mustafa, Ritesh Kumar, Janta Devi, Burhanuddin Sohail Rangwala, Syed Muhammad Sinaan Ali, Adarsh Raja, Javed Iqbal, Mirha Ali, et al.

    Glioblastoma (GB), the most common malignant brain tumour, has a poor prognosis despite advances in treatment. Standard management involves surgery followe


  • Erratum to ‘Role of nanotechnology in neurosurgery: A review of recent advances and their applications’ [World Neurosurgery: X (22C) (2024)100298)]

    by Javed Iqbal, Evan Courville, Syed Faraz Kazim, Michael Kogan, Meic H. Schmidt, Christian A. Bowers

  • Open Access

    Role of artificial intelligence in predicting neurological outcomes in postcardiac resuscitation

    by Muhammad Muneeb Mbbs Khawar, Hafiz Mbbs Abdus Saboor, Rahul Mbbs Eric, Nimra Razzaque Mbbs Arain, Saira Bano, Mawada Babiker Mbbs Mohamed Abaker, Batool Iqtidar Mbbs Siddiqui, Reynaldo Reynoso Figueroa, Srija Reddy Mbbs Koppula, Hira Mbbs Fatima, et al.

    Being an extremely high mortality rate condition, cardiac arrest cases have rightfully been evaluated via various studies and scoring factors for effective resuscitative practices and neurological outcomes postresuscitation. This narrative review aims to explore the role of artificial intelligence (AI) in predicting neurological outcomes postcardiac resuscitation. The methodology involved a detailed review of all relevant recent studies of AI, different machine learning algorithms, prediction tools, and assessing their benefit in predicting neurological outcomes in postcardiac resuscitation cases as compared to more traditional prognostic scoring systems and tools. Previously, outcome determining clinical, blood, and radiological factors were prone to other influencing factors like limited accuracy and time constraints. Studies conducted also emphasized that to predict poor neurological outcomes, a more multimodal approach helped adjust for confounding factors, interpret diverse datasets, and provide a reliable prognosis, which only demonstrates the need for AI to help overcome challenges faced. Advanced machine learning algorithms like artificial neural networks (ANN) using supervised learning by AI have improved the accuracy of prognostic models outperforming conventional models. Several real-world cases of effective AI-powered algorithm models have been cited here. Studies comparing machine learning tools like XGBoost, AI Watson, hyperspectral imaging, ChatGPT-4, and AI-based gradient boosting have noted their beneficial uses. AI could help reduce workload, healthcare costs, and help personalize care, process vast genetic and lifestyle data and help reduce side effects from treatments. Limitations of AI have been covered extensively in this article, including data quality, bias, privacy issues, and transparency. Our objectives should be to use more diverse data sources, use interpretable data output giving process explanation, validation method, and implement policies to safeguard patient data. Despite the limitations, the advancements already made by AI and its potential in predicting neurological outcomes in postcardiac resuscitation cases has been quite promising and boosts a continually improving system, albeit requiring close human supervision with training and improving models, with plans to educate clinicians, the public and sharing collected data.